Search research articles
Contact Us
Filters
Showing results (401-410 of 428) with videos related to
Page
of 43
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2026
Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up
Sæmundur Rögnvaldsson, Sigrún Thorsteinsdóttir, Elias Eythorsson, et al.
Nature Medicine
|
December 8, 2018
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Guy Ledergor, Assaf Weiner, Mor Zada, et al.
Blood Cancer Discovery
|
February 1, 2023
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
Francesco Maura, Bachisio Ziccheddu, Jenny Z Xiang, et al.
JAMA Oncology
|
September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Nature Cancer
|
November 9, 2023
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Francesco Maura, Eileen M Boyle, David Coffey, et al.
Blood Cancer Discovery
|
June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestry
Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
The Lancet. Oncology
|
December 3, 2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, et al.
Blood Cancer Discovery
|
June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Faith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.
JAMA Oncology
|
July 17, 2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde, Mark Roschewski, Adriana Zingone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Kenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Page
of 43
Search research articles
Search
Showing results (401-410 of 428) with videos related to
Sort By:
Page
of 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2026
Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up
Sæmundur Rögnvaldsson, Sigrún Thorsteinsdóttir, Elias Eythorsson, et al.
Nature Medicine
|
December 8, 2018
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Guy Ledergor, Assaf Weiner, Mor Zada, et al.
Blood Cancer Discovery
|
February 1, 2023
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
Francesco Maura, Bachisio Ziccheddu, Jenny Z Xiang, et al.
JAMA Oncology
|
September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Nature Cancer
|
November 9, 2023
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Francesco Maura, Eileen M Boyle, David Coffey, et al.
Blood Cancer Discovery
|
June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestry
Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
The Lancet. Oncology
|
December 3, 2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S Vincent Rajkumar, Meletios A Dimopoulos, Antonio Palumbo, et al.
Blood Cancer Discovery
|
June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Faith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.
JAMA Oncology
|
July 17, 2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde, Mark Roschewski, Adriana Zingone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Kenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Page
of 43